<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pivmecillinam (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pivmecillinam (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pivmecillinam (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="118110" href="/d/html/118110.html" rel="external">see "Pivmecillinam (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F48874392"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F48874411"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: Note: </b>Limited evidence suggests decreased efficacy compared with other agents; avoid if early pyelonephritis is suspected (IDSA/ESCMID [Gupta 2011]; Nicolle 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Females: <b>Oral: </b> 400 mg 2 to 3 times daily for 3 to 7 days (IDSA/ESCMID [Gupta 2011]; Jansåker 2014; manufacturer's labeling [Canadian]); some experts prefer 400 mg 3 times daily, especially for resistant (eg, extended-spectrum beta-lactamase-producing) organisms (Gupta 2021; Jansåker 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urinary tract infection, recurrent:</i>
<b>Oral:</b> 200 to 400 mg 3 times daily; according to the manufacturer, these doses can also be given 4 times daily, but published data support 3 times daily. The duration is uncertain; the manufacturer warns against long-term use (Bresky 1982; Kalager 1978; Canadian product monograph).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992244"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling, although the manufacturer recommends reducing dose in proportion to degree of loss or renal function. Use with caution and consider plasma level monitoring in patients with severe renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50989514"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustments necessary.</p></div>
<div class="block doe drugH1Div" id="F48874412"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F48874410"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ac615e6-688a-461c-8a9f-5e7703d06ac9">Urinary tract infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection:</b> Children and Adolescents &gt;6 years of age and weight &gt;40 kg: Oral: 20 to 40 mg/kg/day (maximum daily dose: 1,200 mg/day) in 3 divided doses for 3 to 7 days.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51222485"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling, although the manufacturer recommends reducing dose in proportion to degree of loss or renal function. Use with caution and consider plasma level monitoring in patients with severe renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51222486"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustments necessary.</p></div>
<div class="block adr drugH1Div" id="F48842501"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash (including erythematous rash, macular eruption, maculopapular rash), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased plasma carnitine concentrations</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, <i>Clostridioides difficile</i> colitis, dyspepsia, esophageal ulcer, esophagitis, oral mucosa ulcer, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue, headache, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Severe dermatological reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Hypersensitivity reaction (including anaphylactic shock, angioedema)</p></div>
<div class="block coi drugH1Div" id="F48874403"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pivmecillinam, other penicillins and/or cephalosporins, or any component of the formulation; impaired transit through esophagus; genetic metabolism anomalies causing severe carnitine deficiency (eg, carnitine transporter defect, methylmalonic aciduria, propionic acidemia)</p></div>
<div class="block war drugH1Div" id="F48874404"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/hypersensitivity reactions:<b> [Canadian Boxed Warning]: Serious and occasionally fatal hypersensitivity (including angioedema and anaphylaxis) and severe cutaneous adverse reactions (SCAR) have been reported in patients receiving therapy with beta-lactams, including pivmecillinam.</b> Patients with a history of hypersensitivity to multiple allergens may be at increased risk. If an allergic reaction occurs, discontinue therapy and institute appropriate supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severe cutaneous adverse reactions: SCARs (eg, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported; discontinue immediately if a SCAR is suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i> infection (CDI) and pseudomembranous colitis; increased risk of CDI may persist up to 3 months postantibiotic treatment (Hensgens 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Carnitine deficiency: May cause carnitine deficiency with long-term or frequently repeated use. Symptoms may include muscle aches, fatigue, and confusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use caution in patients with porphyria, may induce an acute attack.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution and reduce dose in patients with renal impairment due to decreased clearance; consider monitoring plasma level in patients with severe renal impairment.</p></div>
<div class="block prod-avail drugH1Div" id="F48874419"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Selexid: Health Canada approved July 2016; anticipated availability is unknown.</p></div>
<div class="block adm drugH1Div" id="F48874416"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with at least one-half glass of fluid, without regards to meals.</p></div>
<div class="block admp drugH1Div" id="F52618129"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with at least one-half glass of fluid, without regards to meals.</p></div>
<div class="block use drugH1Div" id="F246283"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection: </b>Treatment of acute uncomplicated cystitis and recurrent urinary tract infection caused by susceptible strains of <i>Escherichia coli</i>, <i>Klebsiella</i> species, <i>Enterobacter</i> species, and <i>Proteus</i> species in adults and children &gt;6 years of age and &gt;40 kg.</p></div>
<div class="block mst drugH1Div" id="F48874390"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Selexid brand name for pivmecillinam [multiple international markets] may be confused with Celexa brand name for citalopram [United States, Canada]; Selectin brand name for pravastatin [Italy]; Selexa brand name for celecoxib [Portugal].</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada–approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F48851772"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F48851769"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May diminish the therapeutic effect of Pivmecillinam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of Pivmecillinam. Specifically, the risk for carnitine deficiency may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F48874401"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mecillinam, the active metabolite of pivmecillinam, crosses the placenta. Low concentrations can be detected in the fetus and amniotic fluid.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of pivmecillinam may be altered; however, dose adjustments are not needed (Heikkilä 1992; Kjer 1986).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Larsen 2001; Muanda 2017a; Muanda 2017b; Nørgaard 2008; Vinther Skriver 2004).</p>
<p style="text-indent:0em;margin-top:2em;">Pivmecillinam may be used for the treatment of urinary tract infections during pregnancy when clinically indicated; other antibiotics may be preferred due to side effect profile (Guinto 2010).</p></div>
<div class="block brc drugH1Div" id="F48874402"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Mecillinam, the active metabolite of pivmecillinam, is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse effects to a breastfed infant are not expected when used in therapeutic doses; the manufacturer notes that pivmecillinam may be used during breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F48874418"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function periodically with prolonged therapy and consider plasma levels in patients with severe renal impairment; hepatic function tests periodically with prolonged therapy; hematologic function periodically with prolonged therapy.</p></div>
<div class="block pha drugH1Div" id="F48874407"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pivmecillinam is a 6-aminopenicillanic acid derivative that is metabolized to the active form of the drug, mecillinam. Mecillinam interferes with the bacterial cell wall and has a mode of action different from other penicillins by exerting high specificity against penicillin-binding protein 2 (PBP-2) in the gram-negative cell wall.</p></div>
<div class="block phk drugH1Div" id="F48874409"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 5% to 10%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrolyzed via non-specific enzymatic esterases in the blood, GI mucosa, and other tissues to its active form, mecillinam</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 60% to 70% (unaffected by food)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 1.5 hours (mecillinam)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% to 70% as mecillinam; almost all within the first 6 hours after dose resulting in urine concentrations &gt;200 mg/L after one 400 mg tablet) and bile</p></div>
<div class="block phksp drugH1Div" id="F51470185"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination of mecillinam is reduced by ~75% in patients with severe renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49056191"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alexid | Apexid | Bacilex | Emcil | Lexipen | Piv | Pivicil | Relexid | Selexid | Shigno</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pivinorm</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Pivmelam | X systo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Penomax | Selexid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pivmecillinam | Selexid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Xsysto</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Beltomecin | Kanorpsin | Melysin | Miztec | Peniamicin | Uromelynam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Pivmelam</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Penomax | Selexid</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Selecid | Selexid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Penomax | Selexid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Selexid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Melysin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6284565">
<a name="6284565"></a>Bresky B, Lincoln K. Long-term treatment with pivmecillinam in patients with recurrent bacteriuria. <i>J Int Med Res</i>. 1982;10(3):179-182. doi:10.1177/030006058201000307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/6284565/pubmed" id="6284565" target="_blank">6284565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20824868">
<a name="20824868"></a>Guinto VT, De Guia B, Festin MR, Dowswell T. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. <i>Cochrane Database Syst Rev</i>. 2010;(9):CD007855. doi: 10.1002/14651858.CD007855.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/20824868/pubmed" id="20824868" target="_blank">20824868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hooton.2021">
<a name="Hooton.2021"></a>Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21292654">
<a name="21292654"></a>Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis</i>. 2011;52(5):e103-120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/21292654/pubmed" id="21292654" target="_blank">21292654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1389936">
<a name="1389936"></a>Heikkila A, Pyykko K, Erkkola R, Iisalo E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. <i>Br J Clin Pharmac</i>. 1992;33(6):629-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/1389936/pubmed" id="1389936" target="_blank">1389936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24107388">
<a name="24107388"></a>Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.<i> J Antimicrob Chemother</i>. 2014;69(3):769-772. doi:10.1093/jac/dkt404</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-204581">
<a name="204581"></a>Kalager T, Bøe E, Digranes A, Høisaether P, Solberg CO. Pivmecillinam treatment of chronic urinary tract infection. <i>Infection</i>. 1978;6(1):21-22. doi:10.1007/BF01641086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/204581/pubmed" id="204581" target="_blank">204581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3811971">
<a name="3811971"></a>Kjer JJ, Ottesen B. Pharmacokinetics of pivmecillinam hydrochloride in pregnant and non-pregnant women.<i> Acta Pharmacol Toxicol (Copenh)</i>. 1986;59(5):430-431.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/3811971/pubmed" id="3811971" target="_blank">3811971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11450863">
<a name="11450863"></a>Larsen H, Nielsen GL, Møller M, Ebbesen F, Schønheyder HC, Sørensen HT. Birth outcome and risk of neonatal hypoglycaemia following in utero exposure to pivmecillinam: a population-based cohort study with 414 exposed pregnancies. <i>Scand J Infect Dis</i>. 2001;33(6):439-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/11450863/pubmed" id="11450863" target="_blank">11450863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3885172">
<a name="3885172"></a>Neu HC. Amdinocillin: a novel penicillin. Antibacterial activity, pharmacology and clinical use. <i>Pharmacotherapy</i>. 1985;5(1):1-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/3885172/pubmed" id="3885172" target="_blank">3885172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12195873">
<a name="12195873"></a>Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. <i>Scand J Infect Dis</i>. 2002;34(7):487-492. doi:10.1080/00365540110080728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/12195873/pubmed" id="12195873" target="_blank">12195873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397462">
<a name="18397462"></a>Nørgaard M, Skriver MV, Sørensen HT, Schønheyder HC, Pedersen L. Risk of miscarriage for pregnant users of pivmecillinam: a population-based case-control study. <i>APMIS</i>. 2008;116(4):278-283. doi: 10.1111/j.1600-0463.2008.00938.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/18397462/pubmed" id="18397462" target="_blank">18397462</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Selexid (pivmecillinam hydrochloride) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15513399">
<a name="15513399"></a>Vinther Skriver M, Nørgaard M, Pedersen L, Carl Schønheyder H, Sørensen HT. Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study. <i>Scand J Infect Dis</i>. 2004;36(10):733-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pivmecillinam-united-states-not-available-drug-information/abstract-text/15513399/pubmed" id="15513399" target="_blank">15513399</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 118047 Version 62.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
